Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin
Author(s) -
Rachel J. Dutton,
April Wayman,
Jun-Rong Wei,
Eric J. Rubin,
Jon Beckwith,
Dana Boyd
Publication year - 2009
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.0912952107
Subject(s) - vitamin k epoxide reductase , mycobacterium tuberculosis , microbiology and biotechnology , warfarin , bacteria , biochemistry , biology , escherichia coli , antibiotics , coagulation , chemistry , tuberculosis , enzyme , medicine , genetics , gene , pathology , atrial fibrillation , cytochrome p450 , cardiology , cyp2c9 , psychiatry
Blood coagulation in humans requires the activity of vitamin K epoxide reductase (VKOR), the target of the anticoagulant warfarin (Coumadin). Bacterial homologs of VKOR were recently found to participate in a pathway leading to disulfide bond formation in secreted proteins of many bacteria. Here we show that the VKOR homolog from the bacteriumMycobacterium tuberculosis , the causative agent of human tuberculosis, is inhibited by warfarin and that warfarin-resistant mutations of mycobacterial VKOR appear in similar locations to mutations found in human patients who require higher doses of warfarin. Deletion of VKOR results in a severe growth defect in mycobacteria, and the growth ofM. tuberculosis is inhibited by warfarin. The bacterial VKOR homolog may represent a target for antibiotics and a model for genetic studies of human VKOR. We present a simple assay inEscherichia coli , based on a disulfide-sensitive β-galactosidase, which can be used to screen for stronger inhibitors of theM. tuberculosis VKOR homolog.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom